Levetiracetam Ametas

Levetiracetam, the active ingredient in Levetiracetam Ametas, is an anticonvulsant presented as an oral tablet for oral use. It treats various seizure types in patients with epilepsy. GNH USA supplies Levetiracetam Ametas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an anticonvulsant that acts on neuronal excitability to control seizure activity. Partial‑onset seizures: reduces seizure frequency in focal epilepsy. Generalized tonic‑clonic seizures: helps prevent convulsive episodes. Myoclonic seizures: decreases rapid, involuntary muscle jerks associated with certain epilepsy syndromes.

Levetiracetam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired. - Somnolence: increased sleepiness. - Headache: mild to moderate pain. - Irritability: mood changes or agitation. - Nausea: upset stomach.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, anaphylaxis. - Stevens‑Johnson syndrome: severe skin eruption. - Blood dyscrasias: neutropenia or leukopenia. - Mood changes: depression, suicidal thoughts. - Rash with systemic symptoms: fever, organ involvement. - Hepatic dysfunction: abnormal liver enzymes.

Levetiracetam requires careful consideration in specific clinical situations. - Renal impairment: dose adjustment may be necessary. - Hepatic disease: monitor liver function tests. - Psychiatric symptoms: watch for depression or mood swings. - Concomitant CNS depressants: may increase sedation. - Pregnancy: risk unknown; discuss with a healthcare professional. - Store at ambient temperature: keep in original container, protect from moisture.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: enzyme induction reduces levetiracetam levels. - Phenytoin: enzyme induction may lower efficacy. - Phenobarbital: induces metabolism, decreasing drug exposure. - Rifampin: strong inducer, may diminish therapeutic effect. - St. John’s wort: herbal inducer that can reduce plasma concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression. - Sedative antihistamines: increased drowsiness. - Opioids: enhanced sedation risk. - Benzodiazepines: potential for excessive sedation. - Antidepressants (SSRIs): monitor for mood changes.